DOBI MEDICAL SYSTEMS NAMES LEADING ANGIOGENISIS EXPERT TO ITS SCIENTIFIC ADVISORY GROUP
Mahwah, New Jersey, July 24, 2001. DOBI Medical Systems, LLC, the high-tech medical device company that has developed a unique means of differentiating malignant from benign tumors in the breast by detecting angiogenesis, announced today that it has named William W. Li, M.D. to its Scientific and Medical Advisory Group. Dr. Li joins David Cheresh, Ph.D., Richard Davies, M.D. and Bruce Lepp, Pharm.D. as the Companyâs Scientific and Medical Advisors.
Dr. Li is President and Medical Director of the Angiogenesis Foundation in Cambridge,Massachusetts, which he co-founded in 1994. The mission of the Angiogenesis Foundation is to improve global health by facilitating the development and application of angiogenesis-based medicine. Angiogenesis, or the growth of new blood vessels within the human body, is involved in many of societyâs most significant diseases, including cancer, heart disease, blindness, arthritis, and more than 70 other conditions. " I am pleased that DOBI Medical Systems has made practical use of the knowledge of angiogenesis," said Dr. Li. "
A worldwide expert on angiogenesis, Dr. Li has lectured widely and published numerous reports, abstracts, reviews and book chapters on such topics as the growth control mechanisms of the vascular system and the role of angiogenesis in cancer metastases, ocular disease, arthritis, psoriasis, coronary collateral blood vessel formation, stroke and wound healing. Dr. Li graduated cum laude from Harvard College, received his M.D. degree from the University of Pittsburgh School of Medicine and served his medical internship and residency at Massachusetts General Hospital.
In announcing Dr. Li's appointment, Phillip C. Thomas, President and Chief Executive Officer of DOBI Medical Systems said, Dr. Li is one of the foremost experts on the diagnostic and therapeutic implications of the angiogenesis process. His unique perspective on angiogenesis÷from core science to broad application will enhance DOBI Medical Systems' ability to successfully bring our angiogenesis-based breast imaging system to market next year.
About DOBI Medical Systems
Except for historical information contained herein, the matters discussed in this news release may contain forward-looking statements that involve risks and uncertainties. The forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are not guarantees of future performance due to factors that could cause actual results to differ materially, including but not limited to, results of future clinical trials, technical risks associated with new technology development, government regulatory approval, market acceptance of our product, competition and technological change.
For further information:
DOBI Medical International